Axonics Modulation Technologies, Inc. (AXNX)
| Market Cap | 2.06B |
| Revenue (ttm) | 86.70M |
| Net Income (ttm) | -66.32M |
| Shares Out | 38.83M |
| EPS (ttm) | -1.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 20 |
| Last Price | $50.76 |
| Previous Close | $51.65 |
| Change ($) | -0.90 |
| Change (%) | -1.73% |
| Day's Open | 51.85 |
| Day's Range | 50.72 - 52.50 |
| Day's Volume | 193,225 |
| 52-Week Range | 16.44 - 52.75 |
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call Transcript
Axonics (AXNX) delivered earnings and revenue surprises of 53.85% and 60.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
Down Session Has Bullish Undertones
Stock indexes didn’t give up much ground Tuesday after strong gains Monday.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q2 2020 Results - Earnings Call Transcript
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodu...
Axonics Modulation Technologies Inc (NASDAQ: AXNX) shares are trading higher on Wednesday.
As of late, it has definitely been a great time to be an investor in Axonics Modulation Technologies.
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q1 2020 Results - Earnings Call Transcript
Axonics (AXNX) delivered earnings and revenue surprises of 23.21% and 87.56%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q4 2019 Results - Earnings Call Transcript
Axonics (AXNX) delivered earnings and revenue surprises of -17.19% and -0.54%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
A sneak peek at its fourth-quarter financial performance is fueling investors' optimism.
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2019 Results - Earnings Call Transcript
Axonics (AXNX) delivered earnings and revenue surprises of -21.92% and -9.91%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Shares jump after the medical device maker announces that it has secured an important regulatory win.
There may be a good investment opportunity in an Irvine, California-based startup that is challenging medical technology giant Medtronic (NYSE:MDT) with what appears to be a superior device to...
Axonics (AXNX) expects to improve performance on the positive outcome of the study.
CEO of Axonics Modulation Technologies Inc (30-Year Financial, Insider Trades) Raymond W Cohen (insider trades) bought 3,500 shares of AXNX on 08/06/2019 at an average price of $30.41 a share.
Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q2 2019 Results - Earnings Call Transcript
This medical device stock has been on a tear since the company's Halloween 2018 IPO.
Axonics Modulation Technologies' (AXNX) CEO Ray Cohen on Q1 2019 Results - Earnings Call Transcript
About AXNX
Axonics Modulation Technologies, a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems in the United States and internationally. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence, and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication ... [Read more...]
| Industry Medical Devices | |
| CEO Raymond Cohen | Employees 302 |
| Stock Exchange NASDAQ | Ticker Symbol AXNX |
Financial Performance
In 2019, AXNX's revenue was $13.82 million, an increase of 1,854.74% compared to the previous year's $707,000. Losses were -$79.94 million, 146.1% more than in 2018.
Analyst Forecasts
According to 9 analysts, the average rating for AXNX stock is "Strong Buy." The 12-month stock price forecast is 62.33, which is an increase of 22.81% from the latest price.